China to remain a headwind in 2025 for J&J MedTech, CFO says
Buoyed by cardiovascular acquisitions, J&J still reported strong 2024 results for its medtech business.
Business & Regulation
Pharma and medtech companies need to team up for wound management
Thermo Fisher completes $912.5m acquisition of CorEvitas
GE HealthCare raises 2023 prospects and targets Alzheimer’s care
Philips gives slight bump to 2023 prospects
The UK government’s road to creating a ‘science superpower’
ArchiMed acquires neurodiagnostic devices provider Natus Medical
Magazine: A choppy history of racial bias in oximetry
